Harmony Biosciences Announces CEO Transition to Support Next Phase of Growth
HRMY sits 58% above its 52-week low of $25.52.
Summary
Harmony Biosciences announced a planned CEO transition, framing it as a move to support the next phase of growth, with current CEO Jeffrey Dayno retiring at the end of the year and Peter Anastasiou named to become President and Chief Executive Officer. The company reiterated its 2026 WAKIX net revenue guidance of $1.0B-$1.04B. This follows a CFO resignation in July and a series of insider stock sales, adding to leadership turnover concerns. The company recently posted record Q2 revenue of $261.3M and reaffirmed $1B+ full-year guidance, so the transition comes from a position of operational strength.
Updates
· SEC 8-K — The 8-K confirms Peter Anastasiou's appointment as CEO effective January 1, 2027, and Jeffrey Dayno's retirement as of December 31, 2026, with Dayno serving as non-executive advisor through 2027.
At the time of this announcement, HRMY was trading at $40.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $25.52 to $43.49. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.